Pristinamycin-induced toxic epidermal necrolysis: A case report.
pristinamycin
severe cutaneous adverse reaction
toxic epidermal necrolysis-Steven-Johnson syndrome
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
17 Nov 2022
17 Nov 2022
Historique:
revised:
25
10
2022
received:
29
07
2022
accepted:
28
10
2022
pubmed:
18
11
2022
medline:
18
11
2022
entrez:
17
11
2022
Statut:
aheadofprint
Résumé
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are acute, life-threatening and rare severe cutaneous adverse reactions induced by drugs in most cases. The drugs most often reported to be implicated in inducing TEN/SJS are allopurinol, antibacterial sulfonamides, antiepileptic drugs and oxicam. Pristinamycin is an oral streptogramin antibiotic with bactericidal activity against Gram-positive bacteria that is rarely linked to TEN. Typically, this condition develops 4-28 days after drug exposure, Herein, we report a case of a 71-year-old female who developed TEN within 3 days of administration of pristinamycin and was managed successfully with supportive care, including intravenous fluids, pain control, prophylactic antibiotics and intravenous methylprednisolone. This case of rapidly developing SJS/TEN after administration of pristinamycin highlights the possibility that these complications can develop within only a few days following ingestion of drugs thought to be probably safe.
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2022 British Pharmacological Society.
Références
Sekula P, Dunant A, Mockenhaupt M, et al. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. J Invest Dermatol. 2013;133(5):1197-1204. doi:10.1038/jid.2012.510
Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharm Therap. 2010;88(1):60-68. doi:10.1038/clpt.2009.252
Lissia M, Mulas P, Bulla A, Rubino C. Toxic epidermal necrolysis (Lyell's disease). Burns. 2010;36(2):152-163. doi:10.1016/j.burns.2009.06.213
Barbaud A, Trechot P, Weber-Muller F, Ulrich G, Commun N, Schmutz JL. Drug skin tests in cutaneous adverse drug reactions to pristinamycin: 29 cases with a study of cross-reactions between synergistins. Contact Dermatitis. 2004;50(1):22-26. doi:10.1111/j.0105-1873.2004.00280.x
Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P, Bastuji-Garin S. SCORTEN: A Severity-of-Illness Score for Toxic Epidermal Necrolysis. J Invest Dermatol. 2000;115(2):149-153. doi:10.1046/j.1523-1747.2000.00061.x
Abdulah R, Suwandiman TF, Handayani N, et al. Incidence, causative drugs, and economic consequences of drug-induced SJS, TEN, and SJS-TEN overlap and potential drug-drug interactions during treatment: a retrospective analysis at an Indonesian referral hospital. TCRM. 2017;13:919-925.
Haute Autorité de Santé - PYOSTACINE (pristinamycine) [Internet]. [cited 2022 Jun 27]. https://www.has-sante.fr/jcms/c_1332090/fr/pyostacine-pristinamycine
Valour F, Boibieux A, Karsenty J, et al. Pristinamycin in the treatment of MSSA bone and joint infection. J Antimicrob Chemother. 2016;71(4):1063-1070. doi:10.1093/jac/dkv457
Dancer SJ, Robb A, Crawford A, Morrison D. Oral streptogramins in the management of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections. J Antimicrob Chemother. 2003;51(3):731-735. doi:10.1093/jac/dkg143
Ng J, Gosbell IB. Successful oral pristinamycin therapy for osteoarticular infections due to methicillin-resistant Staphylococcus aureus (MRSA) and other Staphylococcus spp. J Antimicrob Chemother. 2005;55(6):1008-1012. doi:10.1093/jac/dki108
Chanques G, Girard C, Pinzani V, Jaber S. Fatal pristinamycin-induced toxic epidermal necrolysis (Lyell's syndrome): difficulties in attributing causal association in the polymedicated intensive care unit patient. Acta Anaesthesiol Scand. 2005;49(5):721-722. doi:10.1111/j.1399-6576.2005.00685.x
Kim EJ, Lim H, Park SY, et al. Rapid onset of Stevens-Johnson syndrome and toxic epidermal necrolysis after ingestion of acetaminophen. Asia Pac Allergy. 2014;4(1):68-72. doi:10.5415/apallergy.2014.4.1.68
Angadi SS, Karn A. Ibuprofen induced Stevens-Johnson syndrome-toxic epidermal necrolysis in Nepal. Asia Pac Allergy. 2016;6(1):70-73. doi:10.5415/apallergy.2016.6.1.70